Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 1, 2014, Pages 65-72

  Zhang, Ying Ying ^a,b   Zhou, Xin ^b,c   Ji, Wen Jie ^b,c   Shi, Rui ^b,c   Lu, Rui Yi ^b,c   Li, Jin Long ^b,c   Yang, Guo Hong ^b,c   Luo, Tao ^b,c   Zhang, Jian Qi ^b,c   Zhao, Ji Hong ^b,c   Jiang, Tie Min ^b,c   Li, Yu Ming ^b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury   (China)

Author keywords

Clopidogrel; High on treatment platelet reactivity; MicroRNAs; Platelet function test; Vasodilator stimulated phosphoprotein

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; MICRORNA 223; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CYP2C19 PROTEIN, HUMAN; MICRORNA; MIRN223 MICRORNA, HUMAN; TICLOPIDINE; TROPONIN;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PLATELET REACTIVITY; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOCYTE;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CYTOCHROME P-450 CYP2C19; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TICLOPIDINE; TROPONIN;

EID: 84902381640     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1022-9     Document Type: Article

References (41)

1. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr et al (2012) ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60:645-681. doi:10.1016/j.jacc.2012.06. 004
2. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM (2010) ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation 122:537-557. doi:10.1161/CIR.0b013e3181ee08ed
3. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362. doi:10.1056/NEJMoa0809171
4. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857. doi:10.1001/jama.2009.1232
5. Siller-Matula JM, Lang I, Christ G, Jilma B (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557-1563. doi:10.1016/j.jacc.2008.07.055
6. Tantry US, Kereiakes DJ, Gurbel PA (2011) Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 4:365-380. doi:10.1016/j.jcin. 2010.12.009
7. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G et al (2009) Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 120:2337-2344. doi:10.1161/CIRCULATIONAHA. 109.866533
8. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P et al (2008) Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 52:1052-1059. doi:10.1016/j.jacc.2008.05.054
9. Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA et al (2012) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 33:1241-1249. doi:10.1093/eurheartj/ ehr407
10. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215-233. doi:10.1016/j.cell.2009.01.002
11. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P (2009) Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 16:961-966. doi:10.1038/nsmb.1651
12. Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY et al (2013) Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res 131:508-513. doi:10.1016/j.thromres.2013.02.015
13. Fichtlscherer S, Zeiher AM, Dimmeler S (2011) Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 31:2383-2390. doi:10.1161/ATVBAHA.111.226696
14. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM et al (2012) Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 60:290-299. doi:10.1016/j.jacc.2012.03.056
15. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659-666. doi:10.1093/eurheartj/ehq013
16. Tijsen AJ, Pinto YM, Creemers EE (2012) Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 303:H1085-H1095. doi:10.1152/ajpheart.00191.2012
17. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999-3054. doi:10.1093/eurheartj/ehr236
18. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3:85-92. doi:10.1111/j.1538-7836.2004.01063.x (Pubitemid 41647119)
19. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T et al (2006) High post-treatment platelet reactivity identified lowresponders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4:542-549. doi:10.1111/j.1538-7836.2005.01751.x
20. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5:325-329
21. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B et al (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:295-302. doi:10.1002/ccd.10497 (Pubitemid 36792384)
22. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E et al (2007) The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98:1329-1334 (Pubitemid 350239106)
23. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ et al (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46:1827-1832. doi:10.1016/j.jacc. 2005.07.056 (Pubitemid 41579803)
24. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467-473. doi:10.1016/j.jacc.2011.04.017
25. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS et al (2013) Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 112:595-600. doi:10.1161/CIRCRESAHA.111.300539
26. Curtis AM, FitzGerald GA (2013) Platelet microRNAs: novy Mir* or mired in human complexity? Circ Res 112:576-578. doi:10.1161/CIRCRESAHA.113. 300859
27. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E et al (2013) Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 122:253-261. doi:10.1182/blood-2013-03-492801
28. Boon RA, Vickers KC (2013) Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 33:186-192. doi:10.1161/ATVBAHA.112.300139
29. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N et al (2012) Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 93:633-644. doi:10.1093/cvr/cvs007
30. Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K et al (2013) Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 121:984-995. doi:10.1182/blood-2011-08-374793
31. O'Connell RM, Zhao JL, Rao DS (2011) MicroRNA function in myeloid biology. Blood 118:2960-2969. doi:10.1182/blood-2011-03-291971
32. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V (2012) NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 189:4175-4181. doi:10.4049/jimmunol.1201516
33. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG (2010) MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol 11:799-805. doi:10.1038/ni.1918
34. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H et al (2012) A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation.Circulation 125:2892-2903. doi:10.1161/CIRCULATIONAHA.111.087817
35. Huang BS, Luo QZ, Han Y, Li XB, Cao LJ, Wu LX (2013) microRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor PAX6. Oncol Rep 30:2263-2269. doi:10.3892/or 2013.2683
36. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C et al (2005) A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123:819-831. doi:10.1016/j.cell.2005.09.023 (Pubitemid 41721029)
37. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL et al (2011) MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS ONE 6:e27008. doi:10.1371/journal.pone.0027008
38. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34-45. doi:10.1038/nri3345
39. Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ et al (2012) Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 98:139-144. doi:10.1136/hrt.2011.227272
40. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y et al (2011) Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 4:585-594. doi:10.1161/CIRCINTERVENTIONS.111.962555
41. Lu H, Buchan RJ, Cook SA (2010) MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 86:410-420. doi:10.1093/cvr/cvq010